A drug to treat early-stage Alzheimer's, donanemab, has received a positive opinion from the EMA and is close to authorization in the European Union.
Cristina Petrache
Health
Foto unsplash.com
Always see our news on Google
Donanemab, a new drug developed by Eli Lilly for the treatment of early forms of Alzheimer's disease, has received a favorable opinion from the EMA committee, recommending its authorization. The drug, which is intended for patients who are non-carriers or heterozygous for apolipoprotein E ε4, has been shown in clinical trials to slow the progression of cognitive impairment. The drug will be available as an infusible solution, and common side effects include amyloid-associated imaging abnormalities and headache. The final authorization decision rests with the European Commission.
Sources
Un nou tratament pentru boala Alzheimer în stadii timpurii, aproape de autorizare în UE
Un medicament pentru tratamentul bolii Alzheimer în stadii timpurii, aproape de autorizare în UE
Un medicament pentru tratamentul bolii Alzheimer în stadii timpurii, aproape de autorizare în UE
Latest News
17:07
Călin Georgescu loses challenge against the seizure of his villa. Bucharest Tribunal: application dismissed as unfounded
17:00
The “Rear Admiral August Roman” corvette conducted its first live-fire exercises with its onboard guns in the Black Sea
16:53
France estimates its lowest wine production of the century, hit by drought and extreme temperatures
16:45
Mikel Arteta has extended his contract with Arsenal/ The English champions retain their manager
16:39
The Kremlin's reaction after France's nuclear test: “It is a dead-end road”
See more news
NEWS ON THE SAME TOPICS
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
.webp)
